北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 终止发行股份及支付现金购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况的专项核查意见 北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 终止发行股份及支付现金 终止发行股份及支付现金 购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况 的专项核查意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 终止发行股份及支付现金购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况的专项核查意见 购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况 的专项核查意见 德恒 02F20240602-00007 号 致：嘉必优生物技术（武汉）股份有限公司 北京德恒律师事务所（以下简称"德恒"或"本所"）接受嘉必优生物技术 （武汉）股份有限公司（以下简称"嘉必优"或"上市公司"）之委托，担任嘉必 ...

国泰海通证券股份有限公司 关于嘉必优生物技术（武汉）股份有限公司终止本次交易 相关主体买卖股票情况的自查报告之专项核查意见 鉴于嘉必优生物技术（武汉）股份有限公司（以下简称"上市公司""嘉必 优"）拟通过发行股份及支付现金方式购买上海欧易生物医学科技有限公司 63.2134%股权并发行股份募集配套资金暨关联交易（以下简称"本次交易"）， 上市公司于 2025 年 8 月 29 日召开第四届董事会第八次会议、第四届监事会第 八次会议，审议通过了《关于终止发行股份及支付现金购买资产并募集配套资 金暨关联交易事项并撤回申请文件的议案》《关于公司与交易对方签署相关终止 协议的议案》，同意上市公司终止发行股份及支付现金购买资产并募集配套资金 暨关联交易事项并撤回申请文件，以及与交易对方签署相关终止协议。 根据《上市公司重大资产重组管理办法》《上海证券交易所上市公司自律监 管指引第 6 号——重大资产重组》等相关法律法规的要求，国泰海通证券股份 有限公司（以下简称"国泰海通""独立财务顾问"）作为本次交易的独立财务 顾问，对本次交易相关主体买卖股票的情况进行了核查，具体情况如下： 一、本次交易相关主体买卖股票情况自查期间 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-073 嘉必优生物技术（武汉）股份有限公司 关于终止发行股份及支付现金购买资产并募集配套资金暨关 联交易事项相关主体买卖股票情况自查报告的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"、"上市公司"或 "嘉必优"）拟通过发行股份及支付现金方式，购买王树伟、董栋、肖云平、王 修评、靳超、史贤俊、上海帆易生物科技合伙企业（有限合伙）、宁波梅山保税 港区睿欧投资管理合伙企业（有限合伙）、宁波梅山保税港区欧润企业管理合伙 企业（有限合伙）、上海国药二期股权投资基金合伙企业（有限合伙）、南通东证 瑞象创业投资中心（有限合伙）、苏州鼎石汇泽生物产业投资基金合伙企业（有 限合伙）、上海圣祁投资管理合伙企业（有限合伙）合计持有的上海欧易生物医 学科技有限公司 63.2134%股权并发行股份募集配套资金暨关联交易（以下简称 "本次交易"）。 公司于 2025 年 8 月 29 日召开第四届董事会第八次会议、第四届监事会第 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company has established a strong market position in the production of Arachidonic Acid (ARA) and Docosahexaenoic Acid (DHA), with significant growth potential driven by domestic and international demand [8][13]. - The company is expected to benefit from the expiration of patents held by competitors, allowing for increased market share and revenue growth [8][47]. - The financial forecasts indicate robust revenue and profit growth, with a projected revenue increase from 7.00 billion yuan in 2025 to 9.43 billion yuan in 2027, and net profit rising from 1.76 billion yuan to 2.55 billion yuan in the same period [1][8]. Summary by Sections 1. Company Overview - Founded in 2004, the company has pioneered the industrialization of ARA, DHA, and other products, with applications in human nutrition, animal nutrition, and personal care [8][13]. - The company has established long-term partnerships with global nutrition and dairy companies, exporting products to over 30 countries [8][13]. 2. Market Position and Growth - The company holds a market share of 13.5% globally and over 50% domestically in the ARA sector as of 2021, with expectations for further growth due to patent expirations of competitors [47]. - The domestic ARA market has shown a CAGR of 9.85% from 2015 to 2021, driven by rising disposable incomes and regulatory changes [46]. 3. Financial Performance - Revenue is projected to grow from 443.80 million yuan in 2023 to 942.93 million yuan by 2027, with a CAGR of 25.19% from 2023 to 2024 [1]. - Net profit is expected to increase from 91.37 million yuan in 2023 to 255.02 million yuan by 2027, reflecting a strong CAGR of 41.95% in 2024 [1]. 4. Product Segmentation - ARA is projected to account for approximately 70.2% of revenue in 2024, while DHA is expected to contribute 19.6% [15][26]. - The company is diversifying its product offerings, including SA and β-carotene, to enhance its market presence [15][13]. 5. Strategic Initiatives - The company is focusing on expanding its international market presence, particularly in light of the expiration of patents held by competitors, which will allow for competitive pricing and increased market penetration [8][47]. - The strategic direction emphasizes a dual focus on human nutrition and animal nutrition, with ongoing investments in product development and market expansion [8][13].

Group 1 - Dongwu Securities issued a report on September 18, giving a "Buy" rating to Jiabiyou (688089.SH) [1] - The rating is based on three main reasons: diversified layout, technological leadership, and increasing demand [1] - The company is focusing on both internal and external growth strategies [1] Group 2 - The report highlights a dual-driven approach that emphasizes technological advancement [1] - There are concerns regarding market competition and rising raw material costs [1]

Group 1 - The company, Jia Bi You Biotechnology (Wuhan) Co., Ltd., approved a share repurchase plan with a total fund of 15 million to 30 million yuan, with a maximum repurchase price of 25 yuan per share, valid for up to 12 months from the board's approval date [1] - On September 8, 2025, the company adjusted the maximum repurchase price from 24.80 yuan to 35 yuan per share due to changes in annual equity distribution and market conditions [1] - The company executed its first share repurchase on September 9, 2025, buying back 428,091 shares, which is 0.25% of the total share capital, with a total transaction amount of approximately 11.99 million yuan [1]

Group 1 - The company, Jia Bi You (688089.SH), announced its first share buyback on September 9, 2025, through the Shanghai Stock Exchange trading system [1] - A total of 428,100 shares were repurchased, accounting for 0.25% of the company's current total share capital [1] - The highest transaction price was 28.58 yuan per share, while the lowest was 27.25 yuan per share, with a total transaction amount of 11.9991 million yuan (excluding stamp duty and transaction commissions) [1]

2025 年 7 月 10 日，因公司实施 2024 年年度权益分派，第二期回购方案的 回购价格上限由 25.00 元/股（含）调整为 24.80 元/股（含），调整后的回购价格 上限于 2025 年 7 月 10 日生效。具体内容详见公司于 2025 年 7 月 3 日在上海证 券交易所网站(www.sse.com.cn)上披露的《嘉必优生物技术（武汉）股份有限公 司关于 2024 年年度权益分派实施后调整第二期回购股份价格上限的公告》（公告 编号：2025-054）。 证券代码：688089 证券简称：嘉必优 公告编号：2025-072 嘉必优生物技术（武汉）股份有限公司 关于第二期以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 回购方案首次披露日 | 2025 年 1 月 日 | | 25 | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月内 | | | | | 预计回购金额 | 1,500 万元 ...

Core Viewpoint - The company has initiated its first share buyback through the Shanghai Stock Exchange, indicating a strategic move to enhance shareholder value and confidence in its stock performance [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased 428,100 shares, which represents 0.25% of its total share capital [1] - The highest transaction price was 28.58 CNY per share, while the lowest was 27.25 CNY per share [1] - The total amount spent on the buyback was 11.9991 million CNY, excluding transaction fees [1] - **Compliance and Regulations** - The share buyback is in accordance with legal regulations and meets the requirements of the company's second phase of the share repurchase plan [1]

Core Viewpoint - The company has adjusted the upper limit for the repurchase price of its shares to enhance market value and ensure the smooth implementation of the buyback plan [4][7]. Group 1: Buyback Plan Overview - On January 24, 2025, the company approved a plan to repurchase shares using its own funds and a special loan, with a total repurchase amount between RMB 15 million and RMB 30 million, and an initial price limit of RMB 25.00 per share [2]. - The price limit was adjusted to RMB 24.80 per share starting from July 10, 2025, due to annual equity distribution matters [2]. Group 2: Implementation Status - As of the date of the announcement, the company has not yet implemented the share buyback [3]. Group 3: Price Limit Adjustment Details - The upper limit for the repurchase price has been increased from RMB 24.80 to RMB 35.00 per share, effective from September 9, 2025 [6]. - The adjusted price is set at 150% of the average trading price over the previous 30 trading days [4]. - Based on the total share capital of 168,309,120 shares, the estimated minimum and maximum number of shares to be repurchased are approximately 428,571 shares and 857,142 shares, respectively [4]. Group 4: Impact of Price Adjustment - The adjustment of the repurchase price limit is intended to ensure the successful implementation of the buyback and is not expected to negatively impact the company's operations, finances, research and development, profitability, or future development [7]. Group 5: Decision-Making Process - The adjustment was approved during the ninth meeting of the fourth board of directors and the ninth meeting of the fourth supervisory board held on September 8, 2025, without the need for shareholder approval [8][12].